AFT Pharmaceuticals Limited (ASX:AFP)

Market Cap	252.90M
Revenue (ttm)	182.21M
Net Income (ttm)	10.65M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	23.74
Forward PE	18.11
Dividend	0.01 (0.60%)
Ex-Dividend Date	Jun 19, 2024

Volume	6,421
Average Volume	1,011
Open	2.500
Previous Close	2.450
Day's Range	2.420 - 2.500
52-Week Range	2.150 - 3.160
Beta	0.42
RSI	67.18
Earnings Date	May 22, 2025

About AFT Pharmaceuticals

AFT Pharmaceuticals Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical products in New Zealand, Australia, Asia, and internationally. It offers products for use in the areas of allergy, gastrointestinal, cold and flu, digestive health, eye care, first aid, nail care, oral care, pain management, skin care, vitamins, and supplements, as well as other products. The company has collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. AFT Pharma...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 110
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AFP

Financial Performance

In 2023, AFT Pharmaceuticals's revenue was 195.41 million, an increase of 24.75% compared to the previous year's 156.64 million. Earnings were 15.61 million, an increase of 46.51%.

Financial numbers in NZD